A cancer medicine taken by mouth can still put appointments on a patient’s calendar. In this March 16, 2017 retrospective, the relevant decision is FDA’s March 13 approval of ribociclib, sold as Kisqali. It covered postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, with an aromatase inhibitor as initial endocrine-based therapy. [209092Orig1s000ltr][209092s000lbl]
The March 2017 label made clinical support part of that picture. Because ribociclib could prolong the heart’s QT interval, it called for an electrocardiogram before treatment, around day 14 of the first cycle and at the second cycle’s beginning, plus checks as clinically indicated. Starting treatment required a QTcF measurement below 450 milliseconds. [209092s000lbl]
Monitoring extended beyond the heart tracing. The label specified electrolyte checks, liver-function tests and complete blood counts, with scheduled follow-up and additional testing when clinically indicated. Those requirements identify work that an oral prescription does not remove. They do not tell us how many journeys a particular patient made, whether appointments were combined, or what care cost. [209092s000lbl]
FDA also required Novartis to study alternative dosing intended to reduce QT risk without sacrificing efficacy; that was future research, not an accomplished reduction in monitoring. Read together, the letter and label suggest a concrete access question: who would help patients arrange the required checks and the time around them? Neither document measures that burden. This historical account describes the original authorization, not present-day treatment advice. [209092Orig1s000ltr][209092s000lbl]
Source documents
- NDA 209092: KISQALI approval letterhttps://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/209092Orig1s000ltr.pdf
- KISQALI (ribociclib) initial US prescribing informationhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209092s000lbl.pdf